CYL Stock Overview
Manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Artivion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.80 |
| 52 Week High | US$30.75 |
| 52 Week Low | US$19.44 |
| Beta | 1.54 |
| 1 Month Change | 18.38% |
| 3 Month Change | -7.29% |
| 1 Year Change | 13.76% |
| 3 Year Change | 40.91% |
| 5 Year Change | 27.18% |
| Change since IPO | 505.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -5.6% | -0.9% |
| 1Y | 13.8% | -14.7% | 14.1% |
Return vs Industry: CYL exceeded the German Medical Equipment industry which returned -14.7% over the past year.
Return vs Market: CYL matched the German Market which returned 14.1% over the past year.
Price Volatility
| CYL volatility | |
|---|---|
| CYL Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: CYL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CYL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,600 | Pat Mackin | artivion.com |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
Artivion, Inc. Fundamentals Summary
| CYL fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | -€18.79m |
| Revenue (TTM) | €343.39m |
Is CYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYL income statement (TTM) | |
|---|---|
| Revenue | US$390.08m |
| Cost of Revenue | US$140.67m |
| Gross Profit | US$249.41m |
| Other Expenses | US$270.76m |
| Earnings | -US$21.35m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 63.94% |
| Net Profit Margin | -5.47% |
| Debt/Equity Ratio | 107.0% |
How did CYL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 01:21 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Jason Mills | Canaccord Genuity |
| Daniel Stauder | Citizens JMP Securities, LLC |